Enclosed herewith Board Meeting outcomes dated 20th January 2026 for adoption of Unaudited Financial Statement along with Limited Review Report for quarter ended 31st December 2025

Revenue DeclinePat NegativeExceptional ItemEmphasis Of MatterResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.8%Reaction day

₹3.52

prior close

₹3.48

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%-2.0% vs market

Healthcare Service Provider peers, median of 24sector-1.8%-1.1% vs sector

On the reaction day the stock moved 2.0 pts less than Nifty Microcap 250 and 1.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.6

15m

-0.9

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.8-0.8-2.0-1.8-1.1

Next day

+0.0+0.7-0.7+0.3-0.3

-2.0-1.4-0.6+0.2-2.1

-6.3-1.3-5.0-1.8-4.5

-0.9+0.7-1.6-0.8-0.0

-5.4+0.3-5.7-3.4-2.0

-2.3+0.9-3.1-2.1-0.2

15d

+0.6+6.8-6.2-0.2+0.8

-3.4+4.3-7.7+0.0-3.4

-22.4-8.7-13.7-10.1-12.3

-10.5+8.6-19.1-3.3-7.2

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Family Care Hospitals Ltd (formerly Scandent Imaging Ltd) held its Board meeting on January 20, 2026 and approved the unaudited standalone financial results for Q3 FY26 (quarter ended December 31, 2025) along with a limited review report from statutory auditors Rafik and Associates. Q3 FY26 revenue from operations was just ₹6.01 lakhs versus ₹2.83 lakhs in Q3 FY25, while 9-month FY26 revenue collapsed sharply to ₹15.11 lakhs from ₹788.03 lakhs in 9M FY25. The company continued to report losses, with Q3 FY26 net loss of ₹95.74 lakhs (vs ₹209.59 lakhs loss in Q3 FY25) and 9M FY26 loss of ₹625.98 lakhs (vs ₹4,513.59 lakhs loss in 9M FY25, which included ₹7,462 lakhs in exceptional items). EPS stood at ₹(0.18) for Q3 and ₹(1.16) for 9M FY26. The auditor flagged share warrant issuance (1.86 crore warrants on preferential basis, ₹4.67 crore received so far) as an emphasis of matter but did not qualify the review. The Board also recommended re-appointment of three directors including the Whole-Time Director for a second 5-year term, subject to shareholder approval via postal ballot.

Likely market impact

Sharp revenue decline alongside continuing losses points to serious operational challenges and weak business momentum, likely keeping the stock under pressure. The pending ₹14 crore balance from warrant conversion could provide future funding, but shareholder approval via postal ballot for director re-appointments is the next near-term event to watch.